Myomo Makes NYSE American Section 610(b) Public Announcement
March 15 2019 - 04:05PM
Business Wire
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a
wearable medical robotics company that offers increased
functionality for those suffering from neurological disorders and
upper limb paralysis, today announced that, as previously disclosed
in its Annual Report on Form 10-K for the year ended December 31,
2018 filed on March 12, 2019 with the Securities and Exchange
Commission, the audited financial statements for the year ended
December 31, 2018 included in the 10-K contained an audit opinion
from its independent registered public accounting firm, which
included a going concern emphasis of matter paragraph.
This announcement is made pursuant to NYSE American Company
Guide Section 610(b), which requires separate public announcement
of the receipt of an audit opinion containing a going concern
paragraph. This announcement does not represent any change or
amendment to the Company’s consolidated financial statements or to
its Annual Report on Form 10-K for the year ended December 31,
2018.
About MyomoMyomo, Inc. is a wearable medical robotics
company that offers expanded mobility for those suffering from
neurological disorders and upper limb paralysis. Myomo develops and
markets the MyoPro product line. MyoPro is a powered upper limb
orthosis designed to support the arm and restore function to the
weakened or paralyzed arms of patients suffering from CVA stroke,
brachial plexus injury, traumatic brain or spinal cord injury, ALS
or other neuromuscular disease or injury. It is currently the only
marketed device that, sensing a patient’s own EMG signals through
non-invasive sensors on the arm, can restore an individual’s
ability to perform activities of daily living, including feeding
themselves, carrying objects and doing household tasks. Many are
able to return to work, live independently and reduce their cost of
care. Myomo is headquartered in Cambridge, Massachusetts, with
sales and clinical professionals across the U.S. For more
information, please visit www.myomo.com.
Forward Looking StatementsThis press release contains
forward-looking statements regarding the Company’s future business
expectations, including the potential benefits of Myomo’s products
for their users, which are subject to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are only predictions and may differ
materially from actual results due to a variety of factors.
These factors include, among other things:
- our sales and commercialization
efforts;
- our ability to achieve reimbursement
from third-party payers for our products;
- our dependence upon external sources
for the financing of our operations;
- our ability to effectively execute our
business plan; and
- our expectations as to our clinical
research program and clinical results.
More information about these and other factors that potentially
could affect our financial results is included in Myomo’s filings
with the Securities and Exchange Commission, including those
contained in the risk factors section of the Company’s annual
report on Form 10-K, subsequent quarterly reports on Form 10-Q and
other filings with the Commission. The Company cautions readers not
to place undue reliance on any such forward-looking statements,
which speak only as of the date made. Although the forward-looking
statements in this release of financial information are based on
our beliefs, assumptions and expectations, taking into account all
information currently available to us, we cannot guarantee future
transactions, results, performance, achievements or outcomes. No
assurance can be made to any investor by anyone that the
expectations reflected in our forward-looking statements will be
attained, or that deviations from them will not be material and
adverse. The Company disclaims any obligation subsequently to
revise any forward-looking statements to reflect events or
circumstances after the date of such statements or to reflect the
occurrence of anticipated or unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190315005008/en/
For Myomo:ir@myomo.comInvestor Relations:Vivian
CervantesPCG Advisory646-863-6274vivian@pcgadvisory.comPublic
Relations:Matter CommunicationsSarah
Karr978-518-4817myomo@matternow.com
Myomo (AMEX:MYO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Myomo (AMEX:MYO)
Historical Stock Chart
From Mar 2023 to Mar 2024